Immatics Nv Stock Fundamentals
| IMTX Stock | USD 4.53 0.15 3.21% |
Immatics NV fundamentals help investors to digest information that contributes to Immatics' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics stock.
Immatics |
Immatics NV Company Profit Margin Analysis
Immatics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Immatics Profit Margin | (0.48) % |
Most of Immatics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Immatics NV has a Profit Margin of -0.483%. This is 95.69% lower than that of the Biotechnology sector and 97.9% lower than that of the Health Care industry. The profit margin for all United States stocks is 61.97% lower than that of the firm.
Immatics NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immatics's current stock value. Our valuation model uses many indicators to compare Immatics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immatics competition to find correlations between indicators driving Immatics's intrinsic value. More Info.Immatics NV is rated fourth overall in return on equity category among its peers. It is rated third overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immatics' earnings, one of the primary drivers of an investment's value.Immatics Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.Immatics is currently under evaluation in profit margin category among its peers.
Immatics Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0828 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 93.65 M | ||||
| Shares Outstanding | 121.55 M | ||||
| Shares Owned By Insiders | 22.16 % | ||||
| Shares Owned By Institutions | 87.50 % | ||||
| Number Of Shares Shorted | 8.82 M | ||||
| Price To Earning | 44.61 X | ||||
| Price To Book | 1.46 X | ||||
| Price To Sales | 4.92 X | ||||
| Revenue | 54 M | ||||
| Gross Profit | (23.99 M) | ||||
| EBITDA | (88.93 M) | ||||
| Net Income | (96.99 M) | ||||
| Cash And Equivalents | 324.38 M | ||||
| Cash Per Share | 5.00 X | ||||
| Total Debt | 15.4 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.95 X | ||||
| Book Value Per Share | 3.71 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Short Ratio | 12.42 X | ||||
| Earnings Per Share | (0.66) X | ||||
| Price To Earnings To Growth | 3.00 X | ||||
| Target Price | 16.42 | ||||
| Number Of Employees | 572 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 568.85 M | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
| Working Capital | 292.82 M | ||||
| Net Asset | 509.96 M |
About Immatics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.